BCNU-CDDP Continuous Infusion Chemotherapy in Recurrent Oligodendroglioma.
- Author:
Sang Min YOUN
1
;
Chang Hun RHEE
;
Seung Hoon LEE
;
Jae Wook SONG
;
Jong Hyun KIM
Author Information
1. Department of Neurosugery, Korea Cancer Center Hospital, Sam-Sung Medical Center, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Oligodendroglioma;
Chemotherapy;
BCNU;
CDDP
- MeSH:
Carmustine;
Drug Therapy*;
Humans;
Nimustine;
Oligodendroglioma*;
Radiotherapy
- From:Journal of Korean Neurosurgical Society
1996;25(3):540-543
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Eight patients with recurrent oligodendroglioma were treated with 1.3-bis(2-chloroethyl) nitrosourea(BCNU) and CDD continuous infusion chemotherapy. They were 5 with benign oligodendrogliomas and 3 with anaplastic oligodendrogliomas. All the recurrent tumors had been treated with surgery and radiotherapy. Four patients had already received chemotherapy with ACNU. Seven of them showed response to continuous infusion chemotherapy. The time from the response to progression was 15 to 67 weeks. No severe complication of the chemotherapy was found. In conclusion, BCNU-CDDP continuous infusion chemotherapy is an effective treatment modality in recurrent oligodendrogliomas.
